Why high risk: Losing money, losses are large next to sales; Less than a month of cash left at its current burn; Bills due within a year exceed short-term assets; 5 offering filings in 6 months (may sell new shares); Auditor change.
Last 12 months: -$1.7M.
Price chart by TradingView.
50 is neutral. Buying by more insiders, top executives and bigger stakes raises it. Selling lowers it; pre-planned sales count less.
SEC filings of any kind. 50 means a normal week.
| Insider | Trade | Shares | Avg price | Value | Owns after | Date |
|---|---|---|---|---|---|---|
CTT PHARMACEUTICAL HOLDINGS, INC.CEO | Buy | 6K | $0.06 | $335 | 9M | Oct 26Filing ↗ |
| ||||||
CTT PHARMACEUTICAL HOLDINGS, INC.CEO | Buy | 2K | $0.06 | $114 | 9M | Oct 15Filing ↗ |
| ||||||
CTT PHARMACEUTICAL HOLDINGS, INC.CEO | Buy | 4K | $0.06 | $204 | 9M | Oct 6Filing ↗ |
| ||||||
CTT PHARMACEUTICAL HOLDINGS, INC.CEO | Buy | 3K | $0.06 | $187 | 9M | Sep 28Filing ↗ |
| ||||||
"Owns after" is the insider's holding right after the trade. Pre-planned (10b5-1) sales are set up months ahead, a weaker signal.
5,880 shares at $0.06 · $335
2,000 shares at $0.06 · $114
3,700 shares at $0.06 · $204
10,100 shares at $0.05 · $455
3,400 shares at $0.06 · $187
10,100 shares at $0.05 · $455
Source: SEC EDGAR filings. For informational purposes. Not investment advice.
Report a problem with this page